PharmaTher Holdings Ltd. (PHRM.CN)
| Previous Close | 0.2650 |
| Open | 0.2700 |
| Bid | 0.2550 x N/A |
| Ask | 0.2800 x N/A |
| Day's Range | 0.2300 - 0.2700 |
| 52 Week Range | 0.1900 - 1.2400 |
| Volume | |
| Avg. Volume | 195,359 |
| Market Cap | 18.592M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 6.75 |
| EPS (TTM) | 0.0400 |
| Earnings Date | Oct. 27, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Baystreet
Stocks in play: PharmaTher Inc
Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The ...
- GlobeNewswire
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de
- GlobeNewswire
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Late
